Press Releases      Articles & Coverage    Events      Press Kit

The AspirinWorks Test and the CHARISMA Trial

The CHARISMA trial published in the peer-reviewed medical journal Circulation directly links increased levels of a powerful urine biomarker to a patient’s risk of heart attack and stroke, promising to improve how millions of people worldwide are treated for cardiovascular disease — and tested for aspirin effect. Read more:

CHARISMA Outcome Study Results Validate Aspirin Effect
Corgenix Medical’s AspirinWorksTest could change how millions worldwide are tested for aspirin effect and treated for heart disease

FACT:	Approximately 25% of individuals are resistant to the effect of aspirin.
FACT:	Many of these patients—and their doctors—are not aware that daily aspirin is having no effect on reducing their risk of a heart attack or stroke.
FACT:	AspirinWorks is the only FDA-cleared test that helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of a urine biomarker called 11-dehydro thromboxane B2. This biomarker is a metabolite of thromboxane (the target of aspirin therapy).

Email us to be included in our news and press release distribution list. For investor information, please visit the Corgenix’ corporate website.